EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer

Alix Tröster, Nathalie Jores, Konstantin S Mineev iD, Sridhar Sreeramulu iD, Michael DiPrima iD, Giovanna Tosato iD, Harald Schwalbe iD

ChemMedChem · 2023-12 · 18 (23)

DOI: 10.1002/cmdc.202300420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 05.10.2023. Verfasst von Alix Tröster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomolecular Magnetic Resonance, Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Max-von-Laue-Str…. Hauptthemen laut MEDLINE: Receptor, EphA2, Colorectal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ephrin type‐A 2 receptor tyrosine kinase (EPHA2) is involved in the development and progression of various cancer types, including colorectal cancer (CRC). There is also evidence that EPHA2 plays a key role in the development of resistance to the endothelial growth factor receptor (EGFR) monoclonal antibody Cetuximab used clinically in CRC. Despite the promising pharmacological potential of EPHA2, only a handful of specific inhibitors are currently available. In this concept paper, general strategies for EPHA2 inhibition with molecules of low molecular weight (small molecules) are described. Furthermore, available examples of inhibiting EPHA2 in CRC using small molecules are summarized, highlighting the potential of this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, EphA2Colorectal NeoplasmsHumansReceptors, Vascular Endothelial Growth Factor

Stichwörter der Autor:innen

EPH receptorscolorectal cancerdrug discoverykinase inhibitors

Substanzen

Receptor, EphA2Receptors, Vascular Endothelial Growth Factor

Autor:innen und Institutionen

  • Center for Biomolecular Magnetic Resonance, Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Max-von-Laue-Straße 7, 60438, Frankfurt am Main, Germany.
  • Laboratory of Cellular Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), 37 Convent Drive, NIH Bethesda Campus Building 37, Room 4124, Bethesda, MD, 20892, USA.

ORCID-Profile: Konstantin S Mineev, Sridhar Sreeramulu, Michael DiPrima, Giovanna Tosato, Harald Schwalbe

Förderung

  • Intramural NIH HHS
  • Horizon 2020 Framework Programme

Zitieren

APA

Tröster, A., Jores, N., Mineev, K. S., Sreeramulu, S., DiPrima, M., Tosato, G., & Schwalbe, H. (2023). Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer. ChemMedChem, 18(23). https://doi.org/10.1002/cmdc.202300420

Vancouver

Tröster A, Jores N, Mineev KS, Sreeramulu S, DiPrima M, Tosato G, et al. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer. ChemMedChem. 2023;18(23). doi:10.1002/cmdc.202300420

BibTeX
@article{Trster2023,
  author = {Tröster, Alix and Jores, Nathalie and Mineev, Konstantin S and Sreeramulu, Sridhar and DiPrima, Michael and Tosato, Giovanna and Schwalbe, Harald},
  title = {Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer},
  journal = {ChemMedChem},
  year = {2023},
  volume = {18},
  number = {23},
  doi = {10.1002/cmdc.202300420}
}
Kostenlos starten →